Introduction: The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worsening in maximum 3–5 sites while all other tumor sites are controlled by systemic therapy. Areas covered: We explore all possible approaches in these settings of patients: the role of local therapies, considering both surgical metastasectomy and/or ablative techniques, the efficacy of systemic therapies and the rationale behind active surveillance. We also discuss ongoing clinical trials in these settings. Expert opinion: Two different strategies are emerging as the most promising for the approach to the oligometastatic/oligoprogressive mRCC patient: (1) the use of immunocheckpoint inhibitors following metastasectomy; (2) the use of stereotactic radiotherapy alone or combined with immunotherapy for oligometastatic disease. The lack of validated biomarkers of response in these mRCC patient subpopulations is opening the way to the employment of novel technologies. Among them, the use of artificial intelligence seems to be the candidate to contribute to precision oncology in patients with mRCC.

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions / Donini, M.; Buti, S.; Massari, F.; Mollica, V.; Rizzo, A.; Montironi, R.; Bersanelli, M.; Santoni, M.. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 20:6(2020), pp. 491-501. [10.1080/14737140.2020.1770601]

Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions

Buti S.;Bersanelli M.;
2020

Abstract

Introduction: The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worsening in maximum 3–5 sites while all other tumor sites are controlled by systemic therapy. Areas covered: We explore all possible approaches in these settings of patients: the role of local therapies, considering both surgical metastasectomy and/or ablative techniques, the efficacy of systemic therapies and the rationale behind active surveillance. We also discuss ongoing clinical trials in these settings. Expert opinion: Two different strategies are emerging as the most promising for the approach to the oligometastatic/oligoprogressive mRCC patient: (1) the use of immunocheckpoint inhibitors following metastasectomy; (2) the use of stereotactic radiotherapy alone or combined with immunotherapy for oligometastatic disease. The lack of validated biomarkers of response in these mRCC patient subpopulations is opening the way to the employment of novel technologies. Among them, the use of artificial intelligence seems to be the candidate to contribute to precision oncology in patients with mRCC.
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions / Donini, M.; Buti, S.; Massari, F.; Mollica, V.; Rizzo, A.; Montironi, R.; Bersanelli, M.; Santoni, M.. - In: EXPERT REVIEW OF ANTICANCER THERAPY. - ISSN 1473-7140. - 20:6(2020), pp. 491-501. [10.1080/14737140.2020.1770601]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2913532
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact